half life of glp 1 Battle GLP-1 delivery technologies Plasma concentrations of glucagon, GLP-1,

doi: 10.1038/s41746-022-00628-3

The improvements were statistically significant and appeared independent of the degree of weight loss

M.BraddockD

Also showed significant reductions in liver fat (up to 82.4%) and improvements in metabolic parameters Phase 3 (TRIUMPH-4) : The Phase 3 TRIUMPH-4 trial confirmed and exceeded Phase 2 results, demonstrating 28.7% mean weight loss at 68 weeks with the 12 mg dose -- the highest reported for any metabolic peptide in a Phase 3 trial Phase 3 program : Additional Phase 3 trials ongoing for obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND) MASLD/MASH : Specific trials underway evaluating liver-related endpoints Phase 3 TRIUMPH-4 data have confirmed the Phase 2 promise, though the full Phase 3 program across all indications is still ongoing

It's crucial to discuss medical history and potential risks with a health care provider before using these medications, as these drugs are not suitable for people with certain medical conditions, including those with a history of medullary thyroid cancer, type 1 diabetes, pancreatitis, or severe gastrointestinal disease

Non-GLP-1 prescription alternatives Not every alternative needs to work through the same mechanism